Reading TMCI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TMCI free→Reading TMCI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TMCI free→QuarterlyIQ Insights · TMCI
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 8, 2026, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective as of the close of business on April 8, 2026, Gaetano M. Guglielmino, Chief Commercial Officer of Treace Medical Concepts, Inc. (the “Company”), will depart from the Company. The Company does not plan to fill the Chief Commercial Officer role. Instead, Mr. Guglielmino’s responsibilities will be assumed by existing employees, and the Senio…
of this Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Results of Operations and Financial Condition. On February 27, 2026, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Results of Operations and Financial Condition. On January 13, 2026, Treace Medical Concepts, Inc. (the "Company") issued a press release regarding certain preliminary unaudited financial results for the quarter and the year-ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes o…
by reference. Pursuant to the terms of the Loan Agreements, the Company’s ability to pay cash dividends on shares of its common stock will be subject to the Company being in compliance with the financial covenant set forth in the Loan Agreements (subject to certain additional exceptions specified in the Loan Agreements).
Termination of a Material Definitive Agreement. On December 17, 2025, in connection with the Company’s entry into the Loan Agreements discussed in
Other Events. On December 16, 2025, the Company’s Board of Directors appointed John K. Bakewell to serve as lead independent director. Mr. Bakewell has served as a member of the Company’s Board since November 2020 and is the Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee. He is an experienced executive with more than 30 years of service across the medical device, diagnostics, specialty pharma and healthcare services sectors. He most recently hel…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Definitive Agreement On December 17, 2025, Treace Medical Concepts, Inc. (the “Company”) entered into (1) a Loan and Security Agreement (the “Term Loan Agreement”) with SLR Investment Corp. (“SLR”) and the lenders thereto, and (2) a Credit Agreement (the “Revolving Loan Agreement” and collectively with the Term Loan Agreement, the “Loan Agreements”) with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL (“SLR-ABL”). The Term Loan Agreement provides a 60 month term…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2025, Richard W. Mott retired from his position as a member of Board of Directors of Treace Medical Concepts, Inc, including his memberships on the Compensation Committee and the Nominating and Corporate Governance Committee, and as Lead Independent Director of the Board. His decision to retire from the Board was for personal reasons…
Results of Operations and Financial Condition. On November 6, 2025, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…
Results of Operations and Financial Condition. On August 7, 2025, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act o…
Results of Operations and Financial Condition. On May 8, 2025, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 2, 2025, James T. Treace provided notice to the board of directors (the “ Board ”) of Treace Medical Concepts, Inc. (the “ Company ”) of his intent to retire from the Board at the expiration of his current term at the 2025 annual meeting of stockholders (the “ 2025 Annual Meeting ”) and to not stand for re-election. Mr. James T. Treace is…
Results of Operations and Financial Condition. On February 27, 2025, Treace Medical Concepts, Inc. (the “Company”) issued a press release regarding its financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.